Home page > Press release
 

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
ARCHIVE PRESS RELEASE
CHIESI’S SUSTAINABILITY REPORT 2022: A YEAR OF TANGIBLE ACHIEVEMENTS FOR PATIENTS, COMMUNITIES, AND THE PLANET
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
Chiesi appoints Giuseppe Accogli as new Group CEO
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
Chiesi tracks actions taken for a healthier, more sustainable future
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Chiesi Group calls for #ActionOverWords in the fight against climate change
New organisational order for the Chiesi Foundation
Chiesi Group receives European Marketing Authorisation for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy fo
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group